Eli Lilly and Co (LLY.N)
19 Jan 2018
Thu, Dec 14 2017
* NSAV SUBSIDIARY SIGNS MAJOR AGREEMENT WITH ELI LILLY AND COMPANY
Eli Lilly and Co on Wednesday forecast 2018 profit and revenue ahead of Wall Street estimates on strong demand for recently launched drugs such as Trulicity and Taltz.
Dec 13 Eli Lilly and Co on Wednesday forecast 2018 earnings largely above analysts' estimates in part due to strong demand for recently launched products such as diabetes drug Trulicity and psoriasis drug Taltz.
BRIEF-FDA Accepts Biologics License Application (BLA) To Review Galcanezumab For The Prevention Of Migraine In Adults
* FDA ACCEPTS BIOLOGICS LICENSE APPLICATION (BLA) TO REVIEW GALCANEZUMAB FOR THE PREVENTION OF MIGRAINE IN ADULTS
Dec 6 NOVO NORDISK A/S CHIEF SCIENTIFIC OFFICER MADS KROGSGAARD THOMSEN MADE FOLLOWING COMMENTS DURING AN INVESTOR CALL FOLLOWING U.S. APPROVAL OF DIABETES DRUG OZEMPIC:
The U.S. Food and Drug Administration on Tuesday approved Novo Nordisk A/S's diabetes drug Ozempic, setting the stage for a heated battle with Eli Lilly & Co's Trulicity.
Dec 5 The U.S. Food and Drug Administration on Tuesday approved Novo Nordisk A/S's diabetes drug Ozempic, setting the stage for a heated battle with Eli Lilly & Co's Trulicity.
* Eli Lilly And Co reports 17.5 percent passive stake in Leap Therapeutics Inc as of November 14 - SEC Filing Source text: (http://bit.ly/2BcO2L7) Further company coverage:
Eli Lilly and Co said on Tuesday it is considering the sale of its Elanco animal health business and expressed optimism that its rejected rheumatoid arthritis drug would pass muster with U.S. regulators when it resubmits its application.
* Eli Lilly says "very optimistic" on U.S. prospect for arthritis drug baricitinib; still sees resubmission to FDA by January Source text for Eikon: Further company coverage: (Reporting By Bill Berkrot)